Organization
- EUCAST statutes
- Steering Committee
- General Committee
- Subcommittees
- National AST Committees (NAC)
- Development Laboratories
- Network Laboratories
Public consultations
EUCAST News
Definitions of S, I and R
Clinical breakpoints and dosing
- About "Clinical breakpoints".
- Rationale documents
- Splitting MIC wild type distributions
- When there are no breakpoints?
- Breakpoints in brackets
- EUCAST setting breakpoints.
Rapid AST in blood cultures
- Calibration files
- RAST from EUCAST in publications
- Methods
- QC
- Breakpoints for short incubation
- Screening for resistance mechanisms with RAST
- FAQ on RAST
Expert rules and expected phenotypes
- Expected phenotypes
Resistance mechanisms
Guidance documents
SOP
MIC and zone distributions and ECOFFs
- Information o distributions
- New and revised ECOFFs
AST of bacteria
- IVDR
- Media preparation
- MIC determination
- Disk diffusion methodology
- Disk diffusion implementation
- Quality Control
- Strains with defined susceptibility
  - S. pneumoniae
  - P. aeruginosa
- Calibration and validation
- Warnings!
- MIC testing services from EUCAST
- Previous versions of documents
AST of mycobacteria
- AMST organisation
- Clinical breakpoints for antimycobacterial agents
- MIC & ECOFFs
- Methods in Mycobacteria
- FAQ Mycobacteria
- RDs
- Scientific publications
- Meetings & Minutes
AST of fungi
- Breakpoints for antifungals
- MIC distributions and ECOFFs
- Methods in antifungal susceptibility testing
- QC AFST Tables
- Rationale documents for antifungals
- Documents for discussion in AFST
- Publications in journals
- Meetings, Minutes and Reports
- Previous versions of documents
AST of phages
- Subcommittee members
AST of veterinary pathogens
- VetCAST rationale documents
- VetCAST meetings
Frequently Asked Questions (FAQ)
Meetings
- EUCAST meetings
Rationale documents and publications
- Rationale Documents
- Consultations
- Publications in journals
- Technical notes
- Posters
- External documents
- Reports
Presentations and statistics
Videos and online seminars
- Online seminars
- Seminar links
- English
- Chinese
Warnings!
Translations
- EUCAST in Serbian
Information for industry
Links and Contacts
- EUCAST Contact form

Guidance Documents

EUCAST Guidance Documents

Guidance on the use of ceftriaxone and cefotaxime in Staphylococcus aureus (24 February, 2025), Previous version (21 February, 2025), Previous version (8 February, 2023).
Infective endocarditis - EUCAST guidance on the reporting of antimicrobial susceptibility testing results (December, 2024).
Guidance on antimicrobial agents for Stenotrophomonas maltophilia (15 November, 2024), Previous version (1 Feb 2012).
Cefiderocol MIC broth microdilution guide (1 January, 2024). See also the Warning on cefiderocol susceptibility testing.
When there are no breakpoints (3 September, 2024), Previous version (29 February, 2024). Previous version (30 June, 2023), Previous version (1 December 2021 - 30 June, 2023), Previous version (5 July, 2016 - 1 December 2021).
Guidance on the use of fosfomycin intravenously (28 May, 2024); Previous version (5 December, 2023).
ATU - the Area of Technical Uncertainty - Guidance to laboratories on how to deal with the ATU in antimicrobial susceptibility testing (originally published 2018; updated 2019, 2020, 2022, 2024, 2025).
Graphs to illustrate ATUs (Updated 17 March, 2025).
Aminopenicillin breakpoints Enterobacterales following revision 2023 - guidance on implementation (Sept 15, 2023).
Setting breakpoints for agent-inhibitor combinations (14 December, 2021). Previous version of Setting breakpoints for agent-inhibitor combinations (2 October, 2017).
Breakpoints in brackets in breakpoint tables (2 December 2021)
Phenotypic screening tests to detect and exclude resistance of clinical relevance (update 22 August, 2022). Previous version (13 June, 2022). Previous version (2 Febr, 2022). Previous version (1 Dec 2021)
Implementation and use of the 2022 revised colistin breakpoints (January, 2022; minor edits on previous version from Nov, 2021)
Legionella pneumophila susceptibility testing (30 May, 2021); previous version Legionella pneumophila susceptibility testing (11 Dec, 2017)
Implementation and use of the 2020 revised aminoglycoside breakpoints (first published 21 Jan, 2020; updated April 2020)
Daptomycin in endocarditis and bloodstream infections caused by enterococci (April 2025; first published 2020: Daptomycin in endocarditis and bloodstream infections caused by enterococci, also available in CMI as a EUCAST position paper; 2020)
Breakpoints for topical use of antimicrobial agents (revised 12 April 2022, 21 Nov, 2019; 22 Dec, 2016)
Guidance for industry on the working order between pharmaceutical industry, EMA and EUCAST (5 May, 2019)
Cefotaxime and ceftazidime disks with and without clavulanic acid for ESBL confirmation (12 February, 2019)
Guidance on tigecycline dosing, 21 July, 2022. Previous version (23 December, 2018)
The 2019 modifications of susceptibility categories S, I and R categories (22 October, 2018).
This presentation also informs laboratories on how to implement the Area of Technical Uncertainty.
EUCAST system for antimicrobial name abbreviations (January 2022). Previous version (13 July, 2018)
Recommendations for colistin (polymyxin E) MIC testing - joint EUCAST and CLSI recommendation (22 March, 2016)
Burkholderia cepacia complex (20 July, 2013)
Oral cephalosporins and Enterobacterales breakpoints (14 July, 2020). Previous version (16 Feb 2012)
Direct susceptibility testing (16 Feb 2012), See also "EUCAST Rapid AST directly from positive blood culture bottles"